Annabel Borley

852 total citations
10 papers, 32 citations indexed

About

Annabel Borley is a scholar working on Oncology, Cancer Research and Dermatology. According to data from OpenAlex, Annabel Borley has authored 10 papers receiving a total of 32 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 3 papers in Cancer Research and 2 papers in Dermatology. Recurrent topics in Annabel Borley's work include Cancer Treatment and Pharmacology (5 papers), HER2/EGFR in Cancer Research (4 papers) and Breast Cancer Treatment Studies (3 papers). Annabel Borley is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), HER2/EGFR in Cancer Research (4 papers) and Breast Cancer Treatment Studies (3 papers). Annabel Borley collaborates with scholars based in United Kingdom. Annabel Borley's co-authors include Gina Dolan, E. Mark Williams, Louise Hanna, Siva Ganesh, Chris Langley, Sharon Jones, David Terry, Helen Passant, Fiona Scott and Angela Swampillai and has published in prestigious journals such as Cancer Research, Annals of Oncology and Circulation Heart Failure.

In The Last Decade

Annabel Borley

9 papers receiving 32 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Annabel Borley United Kingdom	4	14	11	5	4	4	10	32
Ibolya Laczó Hungary	3	14 1.0×	7 0.6×	3 0.6×	6 1.5×		4	30
M Angeles Montero El Salvador	1	9 0.6×	12 1.1×			3 0.8×	3	37
Shazia Hafiz United Kingdom	3	14 1.0×	7 0.6×		3 0.8×	2 0.5×	6	44
Muthukkumaran Thiagarajan Malaysia	3	18 1.3×	14 1.3×			2 0.5×	14	31
Ana Isabel Blanco Orozco Australia	3	23 1.6×	11 1.0×		4 1.0×	2 0.5×	8	36
Thomas Vermeulin France	4	5 0.4×	7 0.6×	8 1.6×	1 0.3×	2 0.5×	12	38
D.-M. Zahm Germany	4	12 0.9×	9 0.8×		3 0.8×	1 0.3×	4	35
Hajer Aounallah-Skhiri Tunisia	4	9 0.6×	4 0.4×		2 0.5×	1 0.3×	10	31
Rangsiya Buasom Thailand	2	19 1.4×	7 0.6×	1 0.2×		2 0.5×	2	33
Mayank Jha United Kingdom	3	16 1.1×	15 1.4×		2 0.5×	3 0.8×	7	21

Countries citing papers authored by Annabel Borley

Since Specialization

Citations

This map shows the geographic impact of Annabel Borley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annabel Borley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annabel Borley more than expected).

Fields of papers citing papers by Annabel Borley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annabel Borley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annabel Borley. The network helps show where Annabel Borley may publish in the future.

Co-authorship network of co-authors of Annabel Borley

This figure shows the co-authorship network connecting the top 25 collaborators of Annabel Borley. A scholar is included among the top collaborators of Annabel Borley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annabel Borley. Annabel Borley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Joshi, Kroopa, Sophie Barrett, Samantha Seymour, et al.. (2024). Abstract PO3-17-12: Safety and efficacy of Atezolizumab in combination with nab-Paclitaxel in patients with PD-L1 positive metastatic or locally advanced triple-negative breast cancer: A pan-UK cancer centre experience. Cancer Research. 84(9_Supplement). PO3–17.

Ghose, Aniruddha, Dongyun Yang, Angela Swampillai, et al.. (2023). 232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. ESMO Open. 8(1). 101420–101420. 3 indexed citations

Kristeleit, Hartmut, Vivek Misra, Mark Baxter, et al.. (2022). Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience – A Multicenter Retrospective Study. Oncology. 100(12). 666–673. 2 indexed citations

Langley, Chris, et al.. (2022). Experiences and opinions of multi-professional non-medical oncology prescribers on post-qualification training: a qualitative study. International Journal of Clinical Pharmacy. 44(3). 698–708. 4 indexed citations

Borley, Annabel, et al.. (2022). Granulocyte colony stimulating factor (G-CSF)-induced aortitis in a patient undergoing adjuvant chemotherapy for breast cancer. BMJ Case Reports. 15(1). e247237–e247237. 3 indexed citations

Henriksen, Peter, Peter Hall, Olga Oikonomidou, et al.. (2022). Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity. Circulation Heart Failure. 15(7). e009445–e009445. 4 indexed citations

Borley, Annabel, et al.. (2020). Identifying Risk Factors for Anthracycline Chemotherapy-induced Phlebitis in Women with Breast Cancer: An Observational Study. Clinical Oncology. 33(4). 230–240. 5 indexed citations

Hanna, Louise, et al.. (2019). Epirubicin chemotherapy in women with breast cancer: Alternating arms for intravenous administration to reduce chemical phlebitis. European Journal of Cancer Care. 28(5). e13114–e13114. 8 indexed citations

Jafri, Mariam, Hartmut Kristeleit, Vivek Misra, et al.. (2018). Eribulin in metastatic breast cancer the UK experience: A multi-centre retrospective 577 patient study. Annals of Oncology. 29. viii100–viii100. 1 indexed citations

10.

Passant, Helen & Annabel Borley. (2013). Adjuvant treatment for breast cancer. Surgery (Oxford). 31(1). 37–40. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact